```html

Pyoderma gangrenosum (PG): Full Guide to Causes, Symptoms, Diagnosis & Treatment

What is Pyoderma gangrenosum?

Pyoderma gangrenosum (PG) is a rare, inflammatory skin disorder that begins as a painful, red papule or pustule and quickly expands into a large ulcer with a rag‑like, undermined border. The condition is not caused by an infection, despite its name; “pyoderma” refers to the presence of pus‑like exudate, and “gangrenosum” describes the necrotic‑appearing tissue. PG is classified as a neutrophilic dermatosis—meaning the immune system sends an excess of neutrophils (a type of white blood cell) into the skin, leading to tissue destruction.

Because the lesions can look similar to infections or vascular ulcers, PG is often misdiagnosed, which delays appropriate therapy. The disease can affect any part of the body but most commonly appears on the legs, arms, or trunk. It is chronic and tends to follow a relapsing‑remitting course.

Common Causes

Most cases of PG are associated with an underlying systemic disorder rather than a single “cause.” The following conditions are most frequently linked to PG (reported in 50‑70 % of patients):

• Inflammatory bowel disease (IBD): ulcerative colitis and Crohn’s disease
• Rheumatoid arthritis and other seronegative spondyloarthropathies
• Hematologic malignancies: acute myeloid leukemia, myelodysplastic syndrome, lymphoma
• Monoclonal gammopathies (e.g., MGUS, multiple myeloma)
• Behçet’s disease
• Autoimmune liver disease (primary biliary cholangitis, autoimmune hepatitis)
• Vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis)
• Paraneoplastic syndromes linked to solid tumors (especially breast and gastrointestinal cancers)
• Genetic syndromes such as PAPA (pyogenic arthritis, PG, and acne) or SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis)
• Medications or trauma that trigger a phenomenon called pathergy (skin injury leading to exaggerated ulceration)

Associated Symptoms

PG rarely appears in isolation. Patients often experience other signs that reflect the underlying disease or the systemic inflammation:

• Fever, chills, or malaise during active ulcer formation
• Joint pain or swelling (arthralgia/arthritis) – especially when linked to IBD or rheumatoid arthritis
• Abdominal pain, diarrhea, and rectal bleeding in patients with ulcerative colitis or Crohn’s disease
• Weight loss and fatigue (common in malignancy‑associated PG)
• Skin lesions elsewhere – erythematous papules, pustules, or nodules that may precede ulceration
• Eye inflammation (uveitis) in some autoimmune conditions
• Peripheral neuropathy or numbness if ulcers develop near nerves

When to See a Doctor

Because PG can progress rapidly and mimic serious infections, early evaluation is essential. Seek medical care promptly if you notice:

• A rapidly enlarging, painful skin sore that develops a purple, undermined border
• Any ulcer that does not improve with standard wound care or antibiotics
• Signs of infection (increased redness, swelling, pus, fever) that persist despite treatment
• New skin lesions after minor trauma, surgery, or a needle stick (possible pathergy)
• Accompanying systemic symptoms such as unexplained fever, night sweats, or severe joint pain

For patients with known IBD, arthritis, or a blood disorder, be especially vigilant—PG may flare when the primary disease is active.

Diagnosis

Diagnosing PG relies on a combination of clinical judgment, exclusion of other conditions, and occasionally skin biopsy. The typical diagnostic pathway includes:

1. Detailed Medical History

• Onset, speed of progression, and location of ulcers
• History of underlying diseases (IBD, arthritis, hematologic disorders)
• Medication list and recent procedures (to assess pathergy risk)

2. Physical Examination

• Evaluation of ulcer characteristics: violaceous undermined edge, purulent base, peripheral erythema
• Search for other skin findings (papules, pustules, nodules)
• Assessment for systemic signs (fever, lymphadenopathy, joint swelling)

3. Laboratory Tests

• Complete blood count (CBC) – may show neutrophilia or anemia
• Inflammatory markers: ESR, CRP (often elevated)
• Autoimmune panel: ANA, ANCA, rheumatoid factor if connective‑tissue disease suspected
• GI work‑up (colonoscopy, fecal calprotectin) when IBD is a concern
• Bone‑marrow biopsy or serum protein electrophoresis if a hematologic malignancy is suspected

4. Skin Biopsy

A deep incisional biopsy of the ulcer edge is usually performed to rule out infection, vasculitis, or malignancy. Histology typically shows a dense neutrophilic infiltrate with dermal edema and necrosis, but there are no specific pathognomonic features for PG.

5. Exclusion of Mimics

Conditions that can look similar include:

• Infectious cellulitis or necrotizing fasciitis
• Vasculitic ulcers (e.g., polyarteritis nodosa)
• Venous or arterial insufficiency ulcers
• Malignancy‑related ulceration (marjolin ulcer)
• Other neutrophilic dermatoses (e.g., Sweet’s syndrome)

Only after these are ruled out is a diagnosis of PG made, often using the updated diagnostic criteria from the Delphi consensus (Miller et al., 2018) which emphasize rapid progression, characteristic border, pathergy, and associated systemic disease.

Treatment Options

Treatment aims to control the abnormal immune response, promote wound healing, and address any underlying disease. Therapy is individualized; most patients need a combination of systemic medication, topical care, and lifestyle measures.

1. Systemic Medications

• Corticosteroids – Prednisone 0.5–1 mg/kg/day is the first‑line oral agent for acute flares. Intravenous methylprednisolone may be used for severe, rapidly spreading ulcers.
• Cyclosporine – 3–5 mg/kg/day; often combined with steroids for faster control, especially when steroids alone are insufficient.
• Biologic agents
  • Infliximab (anti‑TNFα) – effective for PG associated with IBD; typical dose 5 mg/kg at weeks 0, 2, 6, then every 8 weeks.
  • Adalimumab – subcutaneous; alternative anti‑TNF therapy.
  • Ustekinumab (IL‑12/23 inhibitor) – useful in refractory cases, particularly with co‑existing Crohn’s disease.
  • Rituximab (anti‑CD20) – considered for PG linked to hematologic malignancies or severe vasculitis.
• Other immunosuppressants
  • Mycophenolate mofetil, azathioprine, or methotrexate can be used for maintenance or steroid‑sparing.
  • Dapsone (100 mg daily) may help in mild disease with a neutrophilic component.

2. Topical and Local Therapies

• High‑potency topical corticosteroids (e.g., clobetasol 0.05 % ointment) applied to the ulcer edge twice daily.
• Topical tacrolimus 0.1 % ointment for patients who cannot tolerate steroids.
• Local wound care: non‑adhesive dressings, moist‑wound environment, and debridement of necrotic tissue only when performed by an experienced clinician (to avoid worsening pathergy).
• Platelet‑rich plasma (PRP) or autologous skin grafts can be considered for chronic, non‑healing ulcers after inflammation is controlled.

3. Management of Underlying Disease

Optimal control of associated IBD, arthritis, or hematologic disorder markedly reduces PG recurrence. Coordination with a gastroenterologist, rheumatologist, or hematologist is essential.

4. Supportive Care & Lifestyle

• Analgesia: acetaminophen or short courses of opioids for severe pain (under physician supervision).
• Nutrition: high‑protein diet, vitamin C, zinc, and adequate hydration to promote wound healing.
• Smoking cessation – smoking impairs microcirculation and delays ulcer repair.
• Physical therapy to maintain mobility if ulcers are on the lower extremities.

Prevention Tips

Because PG often erupts after skin injury or during a flare of an associated disease, preventive strategies focus on minimizing trauma and keeping the underlying condition well controlled.

• Avoid unnecessary skin trauma – be gentle with skin‑fold cleaning, avoid tight clothing, and use blunt‑tip needles for injections.
• Manage comorbid disease – maintain regular follow‑up for IBD, rheumatoid arthritis, or blood disorders and adhere to prescribed therapy.
• Prompt wound care – treat minor cuts, insect bites, or surgical sites quickly with sterile technique.
• Protect vulnerable areas – use protective padding for elbows, knees, or bony prominences prone to pressure.
• Quit smoking and limit alcohol – both can exacerbate vascular and immune dysfunction.
• Stress reduction – psychological stress may trigger immune flare‑ups; consider mindfulness, yoga, or counseling.
• Regular skin inspections – patients with known PG should check daily for new lesions and report changes immediately.

Emergency Warning Signs

Key Take‑aways

Pyoderma gangrenosum is a rare, immune‑mediated ulcerative skin disease that frequently co‑exists with systemic inflammatory or malignant conditions. Early recognition, thorough evaluation to exclude infection, and prompt immunosuppressive therapy are crucial to prevent extensive tissue loss. Coordination among dermatology, gastroenterology, rheumatology, and hematology teams yields the best outcomes. Patients should be educated about pathergy, maintain vigilant skin care, and know the red‑flag symptoms that demand urgent medical attention.

References

1. Miller, A. C. et al. "Consensus Diagnostic Criteria for Pyoderma Gangrenosum: A Delphi Approach." British Journal of Dermatology, 2018;179(3):699‑706.
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). "Pyoderma Gangrenosum." Updated 2023. niams.nih.gov
3. Mayo Clinic. "Pyoderma gangrenosum." Accessed May 2024. mayoclinic.org
4. Cleveland Clinic. "Pyoderma Gangrenosum: Diagnosis and Treatment." 2022. clevelandclinic.org
5. World Health Organization (WHO). "Neutrophilic Dermatoses." 2021. who.int

```